Research desk / neuro-cognition lens
NAD+ and the Brain in the Research Literature
A neuro watchlist: the Alzheimer's-model and Parkinson's evidence, the IV cognition pilot, and the long-COVID trial — each tagged by how strong its controlled data really is.
The short read
This page covers NAD+ and the brain — what the cognition and neurodegeneration studies measured, read as a watchlist where each finding is rated by evidence strength. Brain NAD+ falls with age, and the precursors NMN and NR are studied to see whether raising it helps neurons [8]. The strongest brain data so far are from animal models; the human data are early. The IV route, the one most marketed for the brain, has the weakest controlled evidence of all [7]. Each finding below is tagged by species and route so a mouse study is never read as a human result.
Why the brain is an NAD+ target
Decreased NAD+ in the brain is a hallmark of aging and is closely associated with neurodegeneration [8]. The salvage enzyme NAMPT is highly expressed in the hippocampus and linked to neural stem and progenitor cell NAD+ biosynthesis, which is part of why NAMPT is studied as a candidate target in neurodegenerative-disease biology [11]. Reviews of NAD+ in Parkinson's disease describe three proposed neuroprotective mechanisms of NAD+ repletion: restoring mitochondrial function in dopaminergic neurons, promoting proteostasis (protein quality control), and immune modulation [8]. This is the mechanistic case; the outcome data below are where it is tested.
The energy-metabolism thread behind the brain case
The brain rationale rests on the same energy biology that shows up in other high-demand tissues. NAD+ is the redox carrier that drives ATP production, and where NAD+ biosynthesis falters, mitochondrial capacity falls with it. In mouse myoblasts and intact skeletal muscle, knocking down the salvage enzyme NAMPT lowered NAD+ and impaired maximal respiratory and oxidative-phosphorylation capacity, while the precursor NR restored NAD+ and raised respiratory capacity [10]. In human muscle, sarcopenia in 119 older men tracked with low NAD+ and reduced mitochondrial oxidative capacity through perturbed biosynthesis and salvage [9]. Neurons are likewise energy-hungry and salvage-dependent, which is why a falling NAD+ pool — and the high hippocampal expression of NAMPT [11] — frames the brain as a plausible NAD+ target. It is mechanism, not proof of cognitive benefit.
The Alzheimer's-model evidence (preclinical)
The clearest mechanistic brain result is preclinical. In APP/PS1 transgenic Alzheimer's-disease mice, NR supplementation for 5 months raised brain NAD+, reduced proinflammatory cytokine expression, decreased microglial and astrocyte activation, lowered NLRP3 inflammasome expression, and improved cognitive and synaptic function — with the effect working through normalization of the cGAS-STING innate-immune pathway [6]. The study also reduced DNA damage, apoptosis, and cellular senescence, and noted that human Alzheimer's fibroblasts showed a similar NAD+-depletion pattern [6]. This is a mouse-model finding: strong on mechanism, not a demonstration of benefit in people.
Parkinson's disease: early human signals
Parkinson's disease research has moved further toward humans, but remains preliminary. Beyond the mechanistic case, preliminary NR trials in Parkinson's-disease patients have shown increased cerebral and whole-blood NAD+ with an association to clinical improvement, while the reviews stress that dedicated clinical trials are still required [8]. The pattern — NAD+ goes up, with a hint of clinical change but no definitive efficacy — recurs across the neuro literature.
Long-COVID: the first dedicated NR RCT
The newest human brain data come from long-COVID. A 24-week double-blind randomized controlled trial in 58 long-COVID patients found that NR significantly elevated NAD+ but did not show a significant group-level difference in cognitive scores versus placebo; within-group improvements in fatigue, sleep quality, depression, and executive function were observed in NR-treated participants [14]. It is the first RCT of NR specifically in a long-COVID population — a meaningful step that nonetheless missed its between-group cognitive endpoint.
NAD+ injections and IV infusions in the literature
The route most marketed for the brain has the least controlled support. The most-cited human cognition data is a pilot: five consecutive daily IV infusions of 750 mg/day improved performance on 6 of 8 neuropsychological tests, versus 2 of 8 for saline [7]. It is a pilot, not a randomized efficacy trial. Infused NAD+ is also cleared from plasma within roughly two hours [7], so any central effect would have to arise from a brief systemic exposure. Compounded injectable NAD+ further carries documented quality risk — the FDA issued a Class I recall of a compounded NAD+ injection for elevated bacterial endotoxin — and such products are unapproved.
IV NAD+ therapy: what controlled data exist
Almost none. The controlled evidence for IV NAD+ therapy is limited to small pilot and retrospective work; the 750 mg/day, 5-day cognition pilot and the 6-hour pharmacokinetic study [7] are the most-cited human examples, and no large randomized trial has established efficacy. The honest read is that IV NAD+ is an unapproved compounded wellness therapy with rapid plasma clearance and documented contamination risk, studied far less rigorously than the oral precursors covered on NMN vs NR precursors.
What is an NAD injection?
An NAD injection or IV infusion delivers NAD+ directly into the bloodstream, used in wellness and clinical settings. Controlled evidence is limited, infused NAD+ is rapidly cleared from plasma within about two hours [7], and compounded injectables are unapproved and carry contamination risk — the FDA issued a Class I recall of one for endotoxin.
Is an NAD+ shot worth it?
The controlled evidence for IV/injectable NAD+ is the weakest in the field. A 5-day, 750 mg/day IV pilot improved 6 of 8 cognitive tests, but rigorous trials are lacking and plasma NAD+ clears within hours [7]. This summarizes the research, not a value judgment for any individual.
When should you inject NAD+?
Published IV protocols are research and clinic infusion schedules — for example, 750 mg/day over several hours for 5 consecutive days [7] — not consumer timing guidance. No human dosing or timing instructions are given here; the figures describe what specific studies administered.
Does NAD IV actually work?
IV NAD+ has the weakest controlled evidence of any route. Pilot data suggest cognitive changes — 6 of 8 tests improved over 5 days at 750 mg/day — but plasma NAD+ is cleared rapidly [7] and large randomized trials are absent, so efficacy is unproven.